CR20230441A - Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid - Google Patents

Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid

Info

Publication number
CR20230441A
CR20230441A CR20230441A CR20230441A CR20230441A CR 20230441 A CR20230441 A CR 20230441A CR 20230441 A CR20230441 A CR 20230441A CR 20230441 A CR20230441 A CR 20230441A CR 20230441 A CR20230441 A CR 20230441A
Authority
CR
Costa Rica
Prior art keywords
methods
cerebrospinal fluid
plasma
detecting
light chain
Prior art date
Application number
CR20230441A
Other languages
English (en)
Inventor
Melissa Budelier
David Holtzman
Randall Bateman
Hong Jiang
Original Assignee
Washington University St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University St Louis filed Critical Washington University St Louis
Publication of CR20230441A publication Critical patent/CR20230441A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona métodos para detectar y cuantificar opcionalmente la Nfl presente en líquido cefalorraquídeo y sangre, y el uso de los métodos para detectar y medir opcionalmente los niveles de biomarcadores de Nfl que indican daño neuronal. También se divulgan anticuerpos anti-Nfl.
CR20230441A 2021-02-10 2022-02-10 Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid CR20230441A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163147833P 2021-02-10 2021-02-10
US202163183417P 2021-05-03 2021-05-03
US202163197826P 2021-06-07 2021-06-07
PCT/US2022/015998 WO2022173965A1 (en) 2021-02-10 2022-02-10 Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid

Publications (1)

Publication Number Publication Date
CR20230441A true CR20230441A (es) 2023-11-10

Family

ID=82837306

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230441A CR20230441A (es) 2021-02-10 2022-02-10 Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid

Country Status (13)

Country Link
US (1) US20250020669A1 (es)
EP (1) EP4291892A4 (es)
JP (1) JP2024507755A (es)
KR (1) KR20230154307A (es)
AU (1) AU2022220697A1 (es)
BR (1) BR112023015991A2 (es)
CA (1) CA3207924A1 (es)
CL (1) CL2023002353A1 (es)
CO (1) CO2023011971A2 (es)
CR (1) CR20230441A (es)
IL (1) IL305068A (es)
MX (1) MX2023009414A (es)
WO (1) WO2022173965A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164711B (zh) * 2023-09-28 2024-01-30 北京凯祥弘康生物科技有限公司 一种抗神经纤维丝轻链蛋白的抗体
KR102908087B1 (ko) * 2023-10-30 2026-01-07 강원대학교산학협력단 항 신경필라멘트 경쇄 항체 결합 금 나노입자를 유효성분으로 포함하는 퇴행성 뇌질환 바이오마커 검출용 조성물
DE102024124992A1 (de) * 2024-09-02 2026-03-05 Forschungszentrum Jülich GmbH Aptamere, aptamerbasierte Sensoren und Verfahren für den Nachweis von Neurofilament Light
CN119529085B (zh) * 2025-01-23 2025-06-03 南京钟鼎生物技术有限公司 抗神经丝轻链蛋白的单克隆抗体组合物及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053723A1 (en) * 2007-08-24 2009-02-26 Shangxi Xiao Peripherin and Neurofilament Light Protein Splice Variants in Amyotrophic Lateral Sclerosis (ALS)
US20170315136A9 (en) * 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20180080945A1 (en) * 2016-09-20 2018-03-22 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
ES2834085T3 (es) * 2016-11-10 2021-06-16 Brain Biomarker Solutions In Gothenburg Ab Métodos para detectar que un individuo está en riesgo de desarrollar una enfermedad neurodegenerativa
WO2018187350A1 (en) * 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
KR20250174711A (ko) * 2018-07-27 2025-12-12 베라바스, 인크. 고갈 및 농축을 위한 방법
EP3909063A4 (en) * 2019-01-09 2022-11-16 Washington University MULTIPLEXED ASSAY AND METHODS OF USE

Also Published As

Publication number Publication date
KR20230154307A (ko) 2023-11-07
IL305068A (en) 2023-10-01
WO2022173965A1 (en) 2022-08-18
AU2022220697A1 (en) 2023-09-21
CL2023002353A1 (es) 2024-03-08
EP4291892A1 (en) 2023-12-20
CO2023011971A2 (es) 2023-09-29
MX2023009414A (es) 2023-10-26
EP4291892A4 (en) 2025-05-07
US20250020669A1 (en) 2025-01-16
BR112023015991A2 (pt) 2024-01-02
JP2024507755A (ja) 2024-02-21
CA3207924A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
CR20230441A (es) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
MX357550B (es) Microarn plasmaticos para la deteccion de cancer colorrectal temprano.
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
NZ606249A (en) Methods and devices with leak detection
IL254331B (en) Sub-pixel and sub-resolution location of defects in sample slices
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
CL2009002114A1 (es) Un método para detectar al menos un olor en una muestra de gas que comprende: reducir, al menos parcialmente, una cantidad de agua en la muestra de gas; y detectar la presencia o ausencia de olor en la muestra; se describe además un aparato para detectar y/o medir olores en una muestra de gas.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
EA201170361A1 (ru) Ценный документ и способ определения степени загрязнения или изнашивания такого документа
MX2014002692A (es) Medicion de desgaste de banda a traves de deteccion de borde de una imagen de cuadriculado.
EA201270608A1 (ru) Способ и устройство для измерения расхода в газопроводах или нефтепроводах
MY182409A (en) Surface inspection method and surface inspection apparatus
MY176182A (en) Biosensor based on measurements of the clustering dynamics of magnetic particles
BR112014031319A2 (pt) aparelho de teste de vazamento e método de teste de vazamento
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
WO2014096942A3 (es) Herramienta inteligente para la detección de perforaciones, cascotas y abolladuras en tuberías de transporte
PH12015501778A1 (en) Markers associated with wnt inhibitors
CN204085352U (zh) 用于快速检验钢管外径上下限的卡规
CL2012001353A1 (es) Método de detección de un evento de soja en una muestra basada en poner en contacto dicha muestra con un polinucleótido específico para el evento aad-12 pdab4468-0416; método para determinar cigocidad de dicho evento en una planta de soja y kit de detección de adn.
BR112014002108A8 (pt) sistema e método para inspecionar uma tubulação submarina
WO2014165003A8 (en) Systems and methods for fluid analysis using electromagnetic energy
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
BR112018009435A2 (pt) detecção de vazamento com oxigênio
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
FR2971846B1 (fr) Procede d'observation d'un echantillon